Udvalget konstaterede, at fordelen ved Viread er baseret på en undersøgelse hos patienter med højt virusindhold, som ikke tidligere havde fået medicin mod hiv, samt undersøgelser, hvor Viread blev anvendt som tillægsbehandling til hiv- medicin, der ikke virkede.
The committee noted that the benefit of Viread is based on one study of patients with high viral loads who had not received any antiviral treatment before, and studies in which Viread was added to existing HIV treatment that was not working.